NeuroEM develops a non-invasive medical device for treating cognitive decline and Alzheimer's disease using Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF). The company's patented wearable device, MemorEM, delivers electromagnetic treatment that breaks up beta-amyloid and p-tau proteins, the toxic proteins at the root of Alzheimer's disease. NeuroEM is the first company to receive FDA Breakthrough Device status for treating Alzheimer's disease, offering a technology-driven alternative to pharmaceutical approaches. The treatment originated from a laboratory discovery where electromagnetic frequencies unexpectedly showed therapeutic effects on toxic brain proteins. Founded in 2013 and headquartered in Tampa, Florida, NeuroEM has raised approximately $9 million in Series A funding from investors including Bluelake, HHS, and New York Angels.
NeuroEM
Series ANeuroEM develops a non-invasive medical device for treating cognitive decline and Alzheimer's disease using Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF). The company's patented wearable device, MemorEM, delivers electromagnetic treatment that breaks up beta-amyloid and p-tau proteins, the toxic proteins at the root of Alzheimer's disease. NeuroEM is the first company to receive FDA…
About
Business model
Wearable Technology > Health and Wellness Devices > Neural,
Disease Self Management > Neurological Disorders > Therapy > Cognitive Training > Device > Wearable,
Neurology > Medical Devices > Therapeutic Devices > Neurodegenerative > Alzheimer Disease
Institutional investors
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.